Anne Marije joined Apollo as an investment director in 2024, based in Luxembourg.
She is a molecular cell biologist by training, with a focus on targeted therapies in oncology. In her previous role as investment analyst at Forbion, she focused on investments in biotech companies that develop first-in-class therapeutics for inflammatory and fibrotic diseases, as well as in oncology.
Her PhD studies focused on aberrant cell cycle regulation and DNA damage signaling in head and neck cancer at the Amsterdam UMC and VU University. She continued her academic tenure in the US where she studied protein interactions in cells undergoing replication stress at the University of Pennsylvania. Subsequently, Anne Marije obtained her own research funding to focus her postdoctoral studies on the development and validation of targeted PROTAC molecules in TP53-mutant cancers at the Thomas Jefferson University in Philadelphia.
Anne Marije holds BSc and MSc degrees from the VU University Amsterdam, focused on biomedical sciences and oncology.
Anne Marije joined Apollo as an investment director in 2024, based in Luxembourg.
She is a molecular cell biologist by training, with a focus on targeted therapies in oncology. In her previous role as investment analyst at Forbion, she focused on investments in biotech companies that develop first-in-class therapeutics for inflammatory and fibrotic diseases, as well as in oncology.
Her PhD studies focused on aberrant cell cycle regulation and DNA damage signaling in head and neck cancer at the Amsterdam UMC and VU University. She continued her academic tenure in the US where she studied protein interactions in cells undergoing replication stress at the University of Pennsylvania. Subsequently, Anne Marije obtained her own research funding to focus her postdoctoral studies on the development and validation of targeted PROTAC molecules in TP53-mutant cancers at the Thomas Jefferson University in Philadelphia.
Anne Marije holds BSc and MSc degrees from the VU University Amsterdam, focused on biomedical sciences and oncology.
